S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:EDSA

Edesa Biotech (EDSA) Stock Price, News & Analysis

$4.15
-0.30 (-6.74%)
(As of 03/28/2024 ET)
Today's Range
$4.12
$4.44
50-Day Range
$4.06
$5.67
52-Week Range
$2.46
$8.61
Volume
10,223 shs
Average Volume
14,295 shs
Market Capitalization
$13.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.00

Edesa Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
839.8% Upside
$39.00 Price Target
Short Interest
Healthy
0.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.19mentions of Edesa Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$20,000 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.32) to ($1.67) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.10 out of 5 stars

Medical Sector

378th out of 938 stocks

Pharmaceutical Preparations Industry

170th out of 423 stocks

EDSA stock logo

About Edesa Biotech Stock (NASDAQ:EDSA)

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

EDSA Stock Price History

EDSA Stock News Headlines

EDSA: Development of EB05 in ARDS Continues…
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Edesa Biotech Inc (EDSA)
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
Edesa Biotech Reports Fiscal Year 2023 Results
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Edesa Biotech Inc EDSA
Edesa Biotech Announces One-for-Seven Reverse Share Split
See More Headlines
Receive EDSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edesa Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/09/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EDSA
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.00
High Stock Price Target
$57.00
Low Stock Price Target
$21.00
Potential Upside/Downside
+839.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-8,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.34 per share

Miscellaneous

Free Float
2,331,000
Market Cap
$13.16 million
Optionable
Not Optionable
Beta
0.33
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

EDSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Edesa Biotech stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edesa Biotech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EDSA shares.
View EDSA analyst ratings
or view top-rated stocks.

What is Edesa Biotech's stock price target for 2024?

2 Wall Street research analysts have issued twelve-month price targets for Edesa Biotech's shares. Their EDSA share price targets range from $21.00 to $57.00. On average, they anticipate the company's share price to reach $39.00 in the next year. This suggests a possible upside of 839.8% from the stock's current price.
View analysts price targets for EDSA
or view top-rated stocks among Wall Street analysts.

How have EDSA shares performed in 2024?

Edesa Biotech's stock was trading at $4.57 on January 1st, 2024. Since then, EDSA stock has decreased by 9.2% and is now trading at $4.15.
View the best growth stocks for 2024 here
.

When is Edesa Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EDSA earnings forecast
.

How were Edesa Biotech's earnings last quarter?

Edesa Biotech, Inc. (NASDAQ:EDSA) announced its earnings results on Friday, February, 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.21) by $0.67.

When did Edesa Biotech's stock split?

Shares of Edesa Biotech reverse split on Wednesday, October 11th 2023. The 1-7 reverse split was announced on Tuesday, October 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Edesa Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edesa Biotech investors own include Pfizer (PFE), AbbVie (ABBV), VBI Vaccines (VBIV), Vaxart (VXRT), Exxon Mobil (XOM), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Sorrento Therapeutics (SRNE), AT&T (T) and Amarin (AMRN).

Who are Edesa Biotech's major shareholders?

Edesa Biotech's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.52%), Vanguard Group Inc. (0.52%) and Dimensional Fund Advisors LP (0.36%). Insiders that own company stock include Der Velden Peter Van, Michael J Brooks and Pardeep Nijhawan.
View institutional ownership trends
.

How do I buy shares of Edesa Biotech?

Shares of EDSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EDSA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners